However, despite melanoma being the solid tumor type most responsive to the anti-PD-1 monoclonal antibody, overall response rates are estimated around 30–33%, indicating that a considerable number of patients do not experience a reduction in tumor burden, resulting in high morbidity and mortality (1, 18, 20–22). This evidence concerns the gene PDCD1 and neoplasm.